(0.48%) 5 246.68 points
(0.32%) 39 558 points
(0.75%) 16 511 points
(0.73%) $78.59
(-0.30%) $2.34
(0.10%) $2 362.20
(0.32%) $28.80
(1.80%) $1 063.40
(-0.01%) $0.924
(0.00%) $10.80
(-0.01%) $0.794
(-0.02%) $91.30
Live Chart Being Loaded With Signals
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer...
Stats | |
---|---|
Today's Volume | 3 242.00 |
Average Volume | 8 894.00 |
Market Cap | 641.62M |
EPS | SEK0 ( 2024-02-28 ) |
Next earnings date | ( SEK0 ) 2024-05-28 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -10.44 |
ATR14 | SEK0.619 (1.18%) |
FluoGuide A/S Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
FluoGuide A/S Financials
Annual | 2023 |
Revenue: | SEK423 000 |
Gross Profit: | SEK423 000 (100.00 %) |
EPS: | SEK-3.22 |
FY | 2023 |
Revenue: | SEK423 000 |
Gross Profit: | SEK423 000 (100.00 %) |
EPS: | SEK-3.22 |
FY | 2022 |
Revenue: | SEK0 |
Gross Profit: | SEK0 (0.00 %) |
EPS: | SEK-2.33 |
FY | 2021 |
Revenue: | SEK0.00 |
Gross Profit: | SEK0.00 (0.00 %) |
EPS: | SEK-2.15 |
Financial Reports:
No articles found.
FluoGuide A/S
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators